STOCK TITAN

Vivos Therapeutics Schedules Second Quarter 2021 Financial Results Conference Call

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

Vivos Therapeutics (NASDAQ: VVOS) will release its second-quarter financial results after market close on August 12, 2021, with a conference call scheduled for 5:00 p.m. ET the same day. This call will cover the company's financial performance, recent milestones, and growth strategy. Vivos specializes in innovative treatments for sleep-disordered breathing, particularly obstructive sleep apnea. The company offers the Vivos System, a non-invasive oral appliance treatment that has benefitted over 19,000 patients worldwide through 1,250 dentists.

Positive
  • Vivos System has proven effective in treating over 19,000 patients worldwide.
  • The company has the potential for growth with innovative treatment solutions.
  • Scheduled financial results release could enhance investor insights.
Negative
  • None.

Call Scheduled for Thursday, August 12, 2021 at 5:00 pm ET

HIGHLANDS RANCH, Colo., Aug. 09, 2021 (GLOBE NEWSWIRE) --  Vivos Therapeutics, Inc. (“the Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (OSA), today announced that it plans to release financial results for the second quarter ended June 30, 2021 after market close on Thursday, August 12, 2021. The Company will conduct a conference call the same day at 5:00 p.m. (Eastern Time) to review the results as well as provide an overview of the Company’s recent milestones and growth strategy.

To access the conference call, please dial (888) 204-4368, or for international callers, (720) 543-0214. A replay will be available shortly after the call and can be accessed by dialing (844) 512-2921, or for international callers, (412) 317-6671. The passcode for the live call and the replay is 3460553. The replay will be available until August 26, 2021.

A live webcast of the conference call can be accessed on Vivos’ website at https://vivoslife.com/investor-relations/. An online archive of the webcast will be available on the Company’s website for 30 days following the call.

About Vivos Therapeutics, Inc.
Vivos Therapeutics Inc. (NASDAQ: VVOS) is a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for adult patients suffering from sleep-disordered breathing, including obstructive sleep apnea (OSA). The Vivos treatment for mild-to-moderate OSA involves a customized oral appliance and protocols called the Vivos System. Vivos believes that its Vivos System oral appliance technology represents the first clinically effective non-surgical, non-invasive, non-pharmaceutical and cost-effective solution for people with mild-to-moderate OSA. Vivos also sells orthodontic appliances for adults and children. Vivos’ oral appliances have proven effective in over 19,000 patients worldwide by more than 1,250 dentists. Combining technologies and protocols that alter the size, shape, and position of the tissues of a patient’s upper airway, the Vivos System opens airway space and may significantly reduce symptoms and conditions associated with mild-to-moderate OSA, such as lowering Apnea Hypopnea Index scores. Vivos also markets and distributes VivosScore, powered by the SleepImage diagnostic technology for Home Sleep Testing in adults and children. The Vivos Integrated Practice (VIP) program offers dentists training and other value-added services in connection with using the Vivos System.

For more information, visit www.vivoslife.com.

Cautionary Note Regarding Forward-Looking Statements
This press release, the earnings conference call referred to herein, and statements of the Company’s management made in connection therewith contain “forward-looking statements” (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended) concerning future events, particularly with respect to the public offering described herein. Words such as “may”, “should”, “expects”, “projects,” “intends”, “plans”, “believes”, “anticipates”, “hopes”, “estimates” and variations of such words and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks and are based upon several assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond Vivos’ control. Actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, the risk factors described in Vivos’ filings with the Securities and Exchange Commission (“SEC”). Vivos’ filings can be obtained free of charge on the SEC’s website at www.sec.gov. Except to the extent required by law, Vivos expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Vivos’ expectations with respect thereto or any change in events, conditions, or circumstances on which any statement is based.

Investor Relations Contact:
Edward Loew
Investor Relations Officer
(602) 903-0095
ed@vivoslife.com

Media Relations Contact:
Caitlin Kasunich / Jenny Robles
KCSA Strategic Communications
(212) 896-1241 / (917) 420-1444
ckasunich@kcsa.com / jrobles@kcsa.com


FAQ

When will Vivos Therapeutics release its second-quarter financial results?

Vivos Therapeutics will release its second-quarter financial results after market close on August 12, 2021.

What time is the Vivos Therapeutics conference call scheduled for?

The conference call for Vivos Therapeutics is scheduled for 5:00 p.m. ET on August 12, 2021.

What is the focus of Vivos Therapeutics?

Vivos Therapeutics focuses on developing and commercializing treatments for sleep-disordered breathing, specifically obstructive sleep apnea.

How many patients have benefited from the Vivos System?

Over 19,000 patients have benefited from the Vivos System through more than 1,250 dentists worldwide.

Vivos Therapeutics, Inc.

NASDAQ:VVOS

VVOS Rankings

VVOS Latest News

VVOS Stock Data

23.26M
4.59M
1.51%
13.72%
2%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States of America
LITTLETON